Table 2.

COVID 19 related allopathic interventions in CTRI registered trials

S. no.	Allopathic intervention (N = 64)	Frequency (%)
1	Acalabrutinib	1 (1.56)
2	BCG vaccine	4 (6.25)
3	Convalescent plasma	10 (15.63)
4	Antiphospholipid antibody (APLA)	1 (1.56)
5	Chloroquine	3 (4.69)
6	Cytokine cocktail therapy	1 (4.69)
7	2-Deoxy-d-Glucose	1 (1.56)
8	C21	1 (1.56)
9	Combination of nitazoxanide and hydroxychloroquine	1 (1.56)
10	Resveratrol-copper and sodium-copper-chlorophyllin	2 (3.13)
11	Favipavir	2 (3.13)
12	Hydroxychloroquine	5 (7.81)
13	Hydroxychloroquine, ribavirin, ST-NS; hydroxychloroquine, ribavirin, ST-S; lopinavir, ritonavir, ribavirin, ST-S	1 (1.56)
14	Hydroxychloroquine, ciclesonide, ivermectin	1 (1.56)
15	Hydroxychloroquine and azithromycin	1 (1.56)
16	IFN alfa-2b	1 (1.56)
17	Imatinib	1 (1.56)
18	Inj Sepsivac	1 (1.56)
19	Immunoglobulin therapy	1 (1.56)
20	Itolizumab	1 (1.56)
21	Ivermectin	6 (9.38)
22	Lithium	1 (1.56)
23	Mycobacterium w	3 (4.69)
24	N-Acetylcysteine	1 (1.56)
25	Nafamostat mesilate	1 (1.56)
26	Niclosamide	1 (1.56)
27	Ozone therapy	1 (1.56)
28	Povidone iodine gargle	1 (1.56)
29	Sofosbuvir	1 (1.56)
30	Tocilizumab	1 (1.56)
31	Lignocaine	1 (1.56)
32	Topical povidone iodine	1 (1.56)
33	Ulinastatin	1 (1.56)
34	Ultraviolet C therapy	1 (1.56)
35	Vitamin D3	2 (3.13)
36	Novel artificial intelligence algorithm	1 (1.56)